New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
ADC Therapeutics SA
ADCT
Shape
US Flag

NYSE

Unprofitable

EPS improving

Unprofitable

EPS improving

291M

Biotechnology

Next Earning date - 05 Nov 2024

291M

Biotechnology

Next Earning date - 05 Nov 2024

3.01USD
Shape0.03 ( 1.01%)
Market Open
favorite-chart

Relative Strenght

46
favorite-chart

Volume Buzz

-59%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

50%

Quote Panel

Shape
Updated October 24, 2024
1W -3.53 % 1M -1.63 % 3M -21.20 % 1Y 362.37 %

Key Metrics

Shape
  • Market Cap

    291.03M


  • Shares Outstanding

    96.69M


  • Share in Float

    79.21M


  • Dividende

    0


  • Earning Date

    05 Nov 2024


  • Price Target

    3.01


  • Average Volume

    365896


  • Beta

    1.59


  • Range

    0.36-6.04


  • Industry

    Biotechnology


  • Website

    https://www.adctherapeutics.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

4.32x

P/S Ratio

-2.17x

P/B Ratio

-0.9

Debt/Equity

-323.6%

Net Margin

$-2.5

EPS

How ADCT compares to sector?

P/E Ratio

Relative Strength

Shape

ADCT

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$84M

Shape383%

2025-Revenue

$1.48

Shape-291%

2025-EPS

$42M

Shape-47%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Cantor Fitzgerald

initialise

Previous: Not converted

2024-05-30

Now: Overweight

Deutsche Bank

downgrade

Previous: Not converted

2023-08-10

Now: Hold

Citigroup

downgrade

Previous: Not converted

2023-08-10

Now: Neutral

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.65
vs -0.59

Q4.22

arrow
arrow

N/A

-0.30
vs -0.39

Q1.23

arrow
arrow

N/A

-0.74
vs -0.36

Q2.23

arrow
arrow

N/A

-0.58
vs -0.73

Q3.23

arrow
arrow

N/A

-0.58
vs -0.65

Q4.23

arrow
arrow

N/A

-1.03
vs -0.30

Q1.24

arrow
arrow

N/A

-0.56
vs -0.74

Q2.24

arrow
arrow

N/A

-0.38
vs -0.58

Q3.24

arrow
arrow

N/A

-0.38
vs -0.58

Q4.24

arrow
arrow

N/A

-0.38
vs -1.03

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+481%

76.3M  vs 13.1M

Q4.22

arrow
arrow

+310%

69.8M  vs 17M

Q1.23

arrow
arrow

-59%

19M  vs 46.5M

Q2.23

arrow
arrow

+12%

19.3M  vs 17.3M

Q3.23

arrow
arrow

-81%

14.5M  vs 76.3M

Q4.23

arrow
arrow

-76%

16.8M  vs 69.8M

Q1.24

arrow
arrow

-5%

18.1M  vs 19M

Q2.24

arrow
arrow

-10%

17.4M  vs 19.3M

Q3.24

arrow
arrow

+27%

18.5M  vs 14.5M

Q4.24

arrow
arrow

+15%

19.2M  vs 16.8M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-48%

-0.48
vs -0.56

Q4.22

arrow
arrow

-27%

-0.27
vs -0.48

Q1.23

arrow
arrow

-158%

-1.58
vs -0.27

Q2.23

arrow
arrow

+549%

5.49
vs -1.58

Q3.23

arrow
arrow

+88%

0.88
vs 5.49

Q4.23

arrow
arrow

+57%

0.57
vs 0.88

Q1.24

arrow
arrow

+24%

0.24
vs 0.57

Q2.24

arrow
arrow

+28%

0.28
vs 0.24

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

63

63
vs 58

9%

Q4.22

arrow
arrow

62

62
vs 63

-2%

Q1.23

arrow
arrow

58

58
vs 62

-6%

Q2.23

arrow
arrow

58

58
vs 58

NA

Q3.23

arrow
arrow

43

43
vs 58

-26%

Q4.23

arrow
arrow

37

37
vs 43

-14%

Q1.24

arrow
arrow

40

40
vs 37

8%

Q2.24

arrow
arrow

78

78
vs 40

95%

Earnings Growth

Latest News